Abbott Laboratories $ABT Shares Sold by Sterling Capital Management LLC

Sterling Capital Management LLC reduced its holdings in shares of Abbott Laboratories (NYSE:ABT) by 6.1% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 194,734 shares of the healthcare product maker’s stock after selling 12,567 shares during the quarter. Sterling Capital Management LLC’s holdings in Abbott Laboratories were worth $19,246,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Manning & Napier Advisors LLC bought a new stake in Abbott Laboratories during the 2nd quarter valued at $31,000. Summit Securities Group LLC grew its position in shares of Abbott Laboratories by 41.3% in the second quarter. Summit Securities Group LLC now owns 404 shares of the healthcare product maker’s stock valued at $37,000 after purchasing an additional 118 shares in the last quarter. Addison Advisors LLC purchased a new position in shares of Abbott Laboratories in the second quarter valued at $40,000. Hoey Investments Inc. raised its stake in shares of Abbott Laboratories by 59.3% during the 1st quarter. Hoey Investments Inc. now owns 446 shares of the healthcare product maker’s stock valued at $46,000 after purchasing an additional 166 shares during the period. Finally, E Fund Management Hong Kong Co. Ltd. raised its stake in shares of Abbott Laboratories by 221.6% during the 2nd quarter. E Fund Management Hong Kong Co. Ltd. now owns 476 shares of the healthcare product maker’s stock valued at $43,000 after purchasing an additional 328 shares during the period. 75.18% of the stock is owned by institutional investors.

Abbott Laboratories News Summary

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: New data presented at the European Society for Medical Oncology showed Abbott’s whole-genome sequencing Oncodetect® test delivered a 30% absolute improvement in sensitivity for detecting colorectal-cancer recurrence within two years of surgery. Patients with detectable molecular residual disease also faced a 10.6-fold higher recurrence risk, supporting the test’s clinical value and Abbott’s broader cancer-care strategy. Abbott Oncodetect ESMO data
• Positive Sentiment: Wells Fargo upgraded its stance to “overweight” and raised its price target to $119, while other analysts retained buy or outperform ratings. These targets imply substantial potential upside and suggest Wall Street views the recent pullback as excessive. Wells Fargo rating
• Neutral Sentiment: Abbott’s pacemaker and molecular-diagnostics markets are projected to grow, providing long-term demand opportunities. However, the reports also identify procedure costs, regulatory hurdles, cybersecurity risks and changing disease prevalence as industry constraints. Pacemaker market forecast
• Negative Sentiment: Investors remain concerned about Abbott’s lowered 2026 sales-growth outlook. Management cited diabetes-related pricing pressure and weakness in the electrophysiology portfolio, issues that overshadowed a third-quarter earnings and revenue performance that broadly met expectations. Abbott 2026 guidance
• Negative Sentiment: Abbott plans to spin off its approximately $8.5 billion Nutrition business by 2027. Although the transaction could sharpen the company’s focus and unlock value, investors face near-term uncertainty over separation costs, portfolio mix and the growth profile of the remaining business. Abbott Nutrition spin-off
• Negative Sentiment: A comparative study claimed Catheter Precision’s LockeT device outperformed Abbott’s Perclose vascular-closure system. The potential competitive risk appears limited without evidence of meaningful revenue impact, but it adds pressure to Abbott’s medical-device franchise. LockeT and Perclose study

Analyst Upgrades and Downgrades

Several research analysts have commented on the company. Robert W. Baird raised their target price on Abbott Laboratories from $121.00 to $123.00 and gave the stock an “outperform” rating in a research note on Thursday. Royal Bank Of Canada decreased their price target on Abbott Laboratories from $130.00 to $125.00 and set an “outperform” rating on the stock in a research report on Thursday. TD Cowen lowered their price target on shares of Abbott Laboratories from $135.00 to $118.00 and set a “buy” rating on the stock in a report on Thursday. BTIG Research cut their price objective on shares of Abbott Laboratories from $134.00 to $125.00 and set a “buy” rating for the company in a research report on Thursday. Finally, Barclays initiated coverage on shares of Abbott Laboratories in a research note on Wednesday, October 7th. They set an “overweight” rating and a $120.00 price objective for the company. Two research analysts have rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and four have given a Hold rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $118.32.

Abbott Laboratories Price Performance

NYSE:ABT traded up $1.19 during trading hours on Friday, hitting $103.70. 10,296,676 shares of the company’s stock traded hands, compared to its average volume of 10,068,537. Abbott Laboratories has a 52 week low of $81.97 and a 52 week high of $132.02. The business’s fifty day simple moving average is $105.15 and its two-hundred day simple moving average is $98.32. The company has a quick ratio of 0.97, a current ratio of 1.38 and a debt-to-equity ratio of 0.57. The firm has a market cap of $179.45 billion, a P/E ratio of 38.70, a P/E/G ratio of 1.90 and a beta of 0.59.

Abbott Laboratories (NYSE:ABT) last announced its earnings results on Wednesday, October 21st. The healthcare product maker reported $1.42 earnings per share for the quarter, hitting analysts’ consensus estimates of $1.42. The business had revenue of $13.01 billion for the quarter, compared to analyst estimates of $12.99 billion. Abbott Laboratories had a return on equity of 17.97% and a net margin of 9.75%. The company’s quarterly revenue was up 14.5% compared to the same quarter last year. During the same period in the prior year, the company earned $1.30 EPS. On average, research analysts anticipate that Abbott Laboratories will post 5.52 earnings per share for the current fiscal year.

Abbott Laboratories Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, November 16th. Stockholders of record on Thursday, October 15th will be issued a dividend of $0.63 per share. The ex-dividend date of this dividend is Thursday, October 15th. This represents a $2.52 annualized dividend and a dividend yield of 2.4%. Abbott Laboratories’s payout ratio is presently 81.55%.

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company that develops, manufactures and markets a broad range of medical products and services. Founded in 1888 by Wallace C. Abbott, the company is headquartered in Abbott Park, Illinois, and serves patients, healthcare providers and consumers in markets around the world.

Abbott operates across four principal businesses: medical devices, diagnostics, nutrition and established pharmaceutical products. Its offerings include glucose-monitoring systems such as FreeStyle Libre; cardiovascular devices, including stents and structural heart products; laboratory and point-of-care diagnostic systems; and branded generic medicines in areas such as gastroenterology, women’s health and cardiometabolic care.

The company’s nutrition portfolio includes infant and pediatric products such as Similac and PediaSure, adult nutritional products such as Ensure, and rehydration products such as Pedialyte.